<scp>G</scp>p<scp>T</scp>x‐1 and [<scp>A</scp>la⁵,<scp>P</scp>he⁶,<scp>L</scp>eu²⁶,<scp>A</scp>rg²⁸]<scp>G</scp>p<scp>T</scp>x‐1, two peptide<scp>N</scp>a_V1.7 inhibitors: analgesic and tolerance properties at the spinal level

Abstract

Our data indicate that the Na_V 1.7 peptide inhibitors GpTx-1 and GpTx-1-71 produce powerful, nontolerance-forming analgesia in preclinical pain models, which might be dependent on the endogenous opioid system. In addition, at the spinal level, the limited side effects imply that these Na_V 1.7 peptide inhibitors could be potentially developed as GpTx-1-based drugs for pain relief.